Cite
HARVARD Citation
Savona, M. et al. (n.d.). Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Leukemia research. pp. S40-S41. [Online].